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Abstract 
End-stage liver disease caused by hepatitis C virus (HCV) infection is a major indication for liver 
transplantation. However, immediately after transplantation the liver graft of viremic patients 
universally becomes infected by circulating virus, resulting in accelerated liver disease 
progression. Currently available direct-acting antiviral therapies have reduced efficacy in 
patients with end-stage liver disease and prophylactic strategies to prevent HCV recurrence are 
still highly needed. 
In this study we compared the ability of two broadly reactive monoclonal antibodies (mAbs), 
designated 3/11 and AP33, recognizing a distinct but overlapping epitope in the viral E2 
glycoprotein to protect humanized mice from a patient-derived HCV challenge. Their 
neutralizing activity was assessed using the HCVpp and HCVcc systems expressing multiple 
patient-derived envelopes and a human-liver chimeric mouse model.  
HCV RNA was readily detected in all control mice challenged with a patient-derived HCV 
genotype 1b isolate, while three out of four AP33-treated mice were completely protected. In 
contrast, only one out of four 3/11-treated mice remained HCV RNA negative throughout the 
observation period, while the other three had a viral load that was indistinguishable from that in 
the control group. The increased in vivo efficacy of AP33 was in line with its higher affinity and 
neutralizing capacity observed in vitro. 
Conclusion: Although mAbs AP33 and 3/11 target the same region in E2, only mAb AP33 can 
efficiently protect from challenge with a heterologous HCV population in vivo. Since mAb AP33 
efficiently neutralizes viral variants that escaped the humoral immune response and re-infected 
the liver graft of transplant patients, it may be a valuable candidate to prevent HCV recurrence. 
In addition our data is valuable for the design of a prophylactic vaccine. 
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Introduction. 
It is estimated that worldwide more than 185 million people are infected with the hepatitis C 
virus (HCV) (1). HCV is a major cause of liver fibrosis and a substantial fraction of chronically 
infected individuals will develop liver cirrhosis. Patients suffering from HCV-induced liver 
cirrhosis have a marked risk of developing hepatocellular carcinoma and developing hepatic 
decompensation. 
Recently clinically licenced direct-acting antivirals (DAA) cure the majority of infected patients 
without major adverse effects. However, several challenges remain: high costs limit access to 
therapy even in high resources settings and certain subgroups of difficult-to-treat patients may 
need adjunctive therapeutic approaches (2). Vaccine development is hampered by viral evasion 
of host immune responses and a vaccine is not available (3). After liver transplantation (LT) in 
patients with detectable serum HCV RNA, the donor liver inevitably becomes infected and 
between 20 and 30% of these patients develop cirrhosis within 5 years after LT. Recently it was 
demonstrated that Sofosbuvir/Ribavirin combination treatment in a pre-transplant setting may 
successfully prevent post-transplant HCV recurrence, with recurrence inversely related to the 
number of consecutive days of undetectable HCV RNA before LT (4). The same combination 
treatment in a post-transplant setting resulted in a sustained virological response in about 60 to 
70% of patients with recurrent HCV infection (5, 6). 
Using a human liver chimeric mouse model (7), we have recently shown that blocking cellular 
receptors could provide a strategy to prevent HCV recurrence after orthotopic LT (8-12). A small 
molecule designated ITX-5061 (iTherX), which blocks the HCV co-receptor SR-BI, is currently 
under clinical investigation in LT patients (13, 14). An alternative approach is to neutralize the 
circulating virus with molecules that target the viral particle (15-20), one could hypothesize this 
approach would have limited off-target effects.  
Previous studies using chimpanzees and humanized mice showed that HCV infection could be 
prevented using polyclonal and monoclonal antibodies (mAbs) (15, 17, 21, 22). Nevertheless, 
the first clinical trials using human polyclonal or monoclonal anti-HCV antibodies were 
disappointing. Although the antibody therapy was safe and well tolerated it had no or little effect 
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on viremia or HCV recurrence (23-26). However, these discouraging results were most likely 
explained by the limited neutralizing capacity or cross-reactive nature of the antibodies used 
leading to viral escape. Meanwhile, several new mAbs have been developed that show broader 
and more potent antiviral activity (22, 27-34). Recently, Chung and co-workers could 
demonstrate that the human mAb MBL-HCV1 delayed the median time to viral rebound 
compared to placebo treatment in HCV-patients undergoing LT (35). Although the in vivo 
neutralizing potential of MBL-HCV1 was clearly demonstrated, the primary endpoint of the study 
– the prevention of allograft HCV infection – was not met, justifying the quest for more potent 
mAbs. 
In the present study we compared the sensitivity of patient-derived HCV strains to two non-
human mAbs (AP33 and 3/11) targeting the same conserved region immediately downstream of 
HVR1 (hypervariable region 1) in E2 (36-41). Given our encouraging in vitro results with AP33, 
its superior neutralizing potential was validated in vivo using chimeric uPA+/+-SCID mice and LT-
escape viral variants. Our in vivo results and the fact that a humanized version of AP33 is 
currently available warrant further exploration of this antibody in a human LT-setting. In addition 
our data is relevant for future rational vaccine design. 
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Materials and Methods 
Ethical approval. Participating subjects gave written informed consent and the study protocol 
was approved by the ethical committees of the Ghent University Hospital (EC # 1994/137) and 
the University of Strasbourg Hospitals (CPP 10-17). The Animal Ethics Committee of the UGent 
Faculty of Medicine and Health Sciences approved all animal experiments. 
 
Primary human hepatocytes, cell lines and monoclonal antibodies. Primary human 
hepatocytes (PHH) were obtained from patients undergoing partial liver resection. Huh7.5.1, 
HEK293FT and HEK293T cell lines have been described previously (42, 43). The isolation and 
production of the anti-HCV E2 mouse mAb AP33 and the rat anti-E2 mAb 3/11 have been 
described previously (36, 38-40). 
 
In vitro experiments. To measure the relative binding affinity of mAbs AP33 and 3/11 to HCV 
E1E2 glycoproteins, a cell-lysate based ELISA was performed. HCVpp and HCVcc 
neutralization assays were performed as described (42, 44, 45). Clonal sequence analysis was 
performed on all HCV-positive mouse samples and the inoculum. 
A detailed description of all in vitro experiments and patient-derived viral variants can be found 
in the online supplement. 
 
In vivo efficacy study. Mice with a humanized liver were generated as described before (46, 
47). Briefly, within 2 weeks after birth homozygous uPA+/+-SCID mice (48) were transplanted 
intrasplenically with approximately 1 million cryopreserved PHH from a commercial source (BD 
Gentest, Erembodegem, Belgium; donor HH223). The extent of liver humanization was 
assessed by quantifying the concentration of human albumin in the mouse plasma by ELISA 
(Bethyl Laboratories, Montgomery, TX). All animals used in this study had human albumin levels 
ranging from 3.2 to 10.0 mg/mL. Passive immunization studies were performed according to a 
previously described protocol (15, 17). In brief, three days before viral challenge with 104 IU of 
mP05 virus, the animals were injected (intra-peritoneal route) with 1 mg of purified mAbs. As 
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previously demonstrated, 3 days after intra-peritoneal injection only a small fraction of the IgG 
load remained in the peritoneum, whereas plasma IgG levels were still high. The bioavailability 
of circulating mAbs in immunized mice is presented in Supplementary Figure 1. Challenge virus 
(mLT_P05) was originally isolated from an HCV-infected patient before LT (patient 5; (45)) and 
passaged in humanized mice (hence the prefix ‘m’) to eliminate any of the patient’s neutralizing 
antibodies. Injection of 104 IU of mLT_P05 virus results in HCV-infection in all tested chimeric 
uPA+/+-SCID mice so far (100% infectious dose). The animals were bled at weekly intervals and 
followed until 8 weeks after infection. Mouse plasma samples were stored at -80°C until 
analysis. The Animal Ethics Committee of the Faculty of Medicine and Health Sciences of the 
Ghent University approved the study protocol. Viral RNA was quantified using the Roche 
COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test (v2.0). Due to dilution of the mouse 
plasma, the limit of detection and limit of quantification were 750 IU/mL. 
 
Statistics. Statistical significance of experimental results was assessed by the Wilcoxon 
matched-pairs signed-ranks test (Fig 1, Fig 2A+B) and the Kruskal-Wallis test (non-
parametric analysis of variance [ANOVA]) with Dunn’s Multiple Comparisons posttest (Fig 
2C) using GraphPad InStat version 3.06 (GraphPad Software).    
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Results 
mAb AP33, but not 3/11, efficiently binds and neutralizes envelopes of patient-derived 
HCV escape variants. Using PHH and HCVpp carrying viral envelope glycoproteins derived 
from HCV-infected patients undergoing LT, we previously demonstrated that in the early phase 
post-transplantation, viral variants characterized by enhanced viral entry and escape from 
autologous antibody-mediated neutralization were able to re-infect the liver graft (45). Here we 
compared the binding and neutralizing activity of two broadly neutralizing anti-E2 mAbs, AP33 
and 3/11, using the envelopes of infectious HCV variants isolated from: (i) patients after LT 
(HCV variants that originate from the re-infected liver graft and are resistant to neutralization by 
autologous serum); and (ii) chimeric mice after challenge with HCV_gt1b from chronically 
infected patients (HCV variants that are selected during transmission to humanized mice). The 
detailed origin of the patient-derived viral variants can be found in the online supplement. While 
mAbs AP33 and 3/11 both recognize a linear, highly conserved region of E2 spanning amino 
acid (AA)-residues 412 to 423, their epitopes are distinct. The relative affinity of these antibodies 
for E2 derived from prototype HCV genotype 1a, 1b and 2a strains or those derived from the LT- 
and CC-patient variants, was determined using the GNA-capture ELISA. Dose-response 
experiments showed that the half maximal effective concentration (EC50) values of both 
antibodies were significantly different (P<0,005), with mAb AP33 having a 3- to 50-fold higher 
apparent affinity depending on the isolate (Figure 1). 
HCVpp expressing envelope glycoproteins from 3 LT_P05-derived viral variants were incubated 
with either mAbs AP33, 3/11 or isotype control IgG before infecting PHHs (Figure 2A). HCVpp 
expressing envelope glycoproteins from prototype gt1a and 2a, and 4 CC-patient-derived gt1b 
viral variants were pre-incubated with the same antibodies before infecting Huh7.5.1 hepatoma 
cells (Figure 2B). AP33 inhibited the entry of patient-derived HCVpp in PHH and Huh7.5.1 cells 
in a dose-dependent manner (Figure 2A-B, Supplementary Table 1). Compared to AP33, the 
neutralizing potential of mAb 3/11 was significantly reduced (P<0.005) and higher antibody 
concentrations were needed to reach comparable levels of inhibition. Similar results were 
obtained using the HCVcc model system using a well-characterized chimera LT_P01_VL/JFH1 
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expressing the structural genes of the HCV-VL strain (P01 patient) (43, 45) and the 
nonstructural genes of JFH1 (Figure 2C). Using this model, which was previously used to 
demonstrate the neutralizing potential of AP33 in hepatocytes and Huh7.5.1 cells (43, 45), the 
reduced neutralizing potential of 3/11 was confirmed (P<0.005). The AA-diversity in the E2-
region spanning AA384-427 (HVR1+minimal epitope) of the patient-derived isolates used in the 
binding and neutralization experiments is illustrated in Figure 2D. Overall, HCVcc-data confirm 
HCVpp-data and suggest that mAb AP33, but not 3/11, efficiently inhibits entry of HCV escape 
variants that are resistant to autologous host responses. 
  
mAb AP33, but not 3/11, efficiently inhibits cell entry of HCVpp expressing envelopes 
from patient variants isolated during the pre-transplantation period. Chronic HCV infection 
is associated with viral quasispecies that contain neutralization escape variants (44, 45). Using 
neutralizing antibodies immediately in the pre-transplantation period as an immunoprophylactic 
approach may reduce the pool of circulating viruses and ultimately prevent HCV recurrence 
after LT. The potential of AP33 to inhibit infection of HCV strains present during the pre-
transplantation period was demonstrated previously (45). Here, the neutralizing potential of 
AP33 and 3/11 was compared using the HCVpp model system and normalized to isotype 
control IgG. All antibodies were pre-incubated at 10 µg/mL with a panel of 20 different HCVpp 
that express envelopes derived from variants isolated from pre-transplant serum of 5 LT-
patients. Eleven out of these 20 patient-derived variants re-infected the liver graft and were 
resistant to autologous antibody neutralization. While AP33 efficiently inhibited infection of all 
HCVpp expressing envelopes of viral variants by up to 100%, 3/11 only partially neutralized 
infection of patient-derived HCVpp. Except for control H77c HCVpp, which was neutralized for 
68%, the level of neutralization of patient-derived HCVpp by 3/11 ranged from 3 to 62%, with 
50% neutralization achieved only for 2 out of 20 variants (P06_VF by 62% and P06_VI by 
54%)(Figure 3). These data demonstrate that AP33, but not 3/11, efficiently inhibits the 
infectivity of HCVpp bearing envelope glycoproteins isolated from different patient-derived viral 
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variants that exist before and after LT. Therefore mAb AP33 is a relevant candidate for 
prevention of liver graft infection. 
 
Lysine-residues at AA-positions 408 and 410 are important for mAb AP33 binding. To 
explain the superior binding and in vitro neutralization potential of mAb AP33 compared to 3/11, 
we investigated crucial binding residues for both mAbs(41). Although both mAbs recognize a 
linear region of E2 spanning AA-residues 412 to 423, their epitopes are distinct. The major 
determinants of AP33 are E2 residues L413, N415, G418 and W420 (39, 40). The critical 
residues for 3/11 binding to E2 are N415, W420 and H421 (39). Since this region is highly 
conserved, these critical residues are conserved in all patient-derived variants. Interestingly, by 
expanding the sequence analysis up- and downstream of AA-region 412-423, we discovered 
additional binding residues for AP33 as well as for 3/11. Using overlapping peptides (15-mer 
with 1 AA overlap) spanning AA-region 406 to 427 of E2, the overall binding pattern for AP33 as 
well as 3/11 differed for gt1a- and gt1b-derived sequences (Figure 4A). The presence of Q412 
and H421 at both ends of the minimal epitope is important for binding of both mAbs. 
Furthermore, residues at AA-positions 408 and 410 represent additional anchor residues. 
Remarkably, the involvement of position 408 is more pronounced in gt1a, whereas position 410 
influences binding in gt1b: (i) absence of K408 in gt1a decreases AP33 as well as 3/11-binding 
(AP33>3/11), (ii) absence of A/T408 in gt1b only slightly reduces AP33-binding and does not 
influence 3/11-binding, (iii) absence of N410 in gt1a has a minor influence on binding of both 
mAbs, (iv) but in gt1b it drastically decreases AP33 as well as 3/11-binding. Based on these 
peptide-binding assays, K-residues at AA-positions 408 and 410 seem important for optimal 
binding of both mAbs. For 3/11 binding, additional anchor residues were observed: (i) absence 
of Q409 reduces binding (gt1a>gt1b), (ii) addition of N423 (gt1b) and A426 enhances binding.  
To unravel whether peptides with good binding potential in Figure 4A (AA408-422, AA409-423 
and AA412-426; marked with an asterisk in Figure 4A) represent the complete mAb-epitope, we 
compared the relative binding affinity of (i) these peptides, (ii) functional full-length E1E2-cell-
lysates (E1E2_FL) and (iii) peptides spanning AA-region 384-447 (Figure 4B). Dose response 
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experiments demonstrate that AP33-binding to AA408-422 and AA384-447 is similar and largely 
exceeds AA412-426-binding, suggesting the presence of additional anchor-residues upstream 
of the minimal epitope (AA412-423). The suboptimal AP33-binding of E1E2_FL suggests 
potential sterical hindrance, probably caused by N-glycosylation at position 417 (termed E2N1, 
only present in the native particle). 3/11 binding of different peptides, on the other hand, never 
equals E1E2_FL binding affinity, suggesting additional, possibly conformation-dependent, 
binding residues in E2. As an alternative explanation, the suboptimal peptide-binding of mAb 
3/11 as compared to the full-length E2 protein could be attributed to the fact that peptides are 
not glycosylated, since it was previously demonstrated that the glycan at position 423 potentially 
contributes to the 3/11 binding (49). 
To confirm the involvement of K-residues at positions 408 and 410, peptides were generated 
with K- or A-substitutions at these positions (Figure 5A). Dose response experiments clearly 
demonstrate a hierarchy in AP33-affinity: K408-K410 > A/T408-K410 > K408-A410 > A/T408-
A410. The 3/11 binding was not influenced by AA-changes at these positions. Since the 
affinity of AP33 for peptides with alanine substitutions at positions 408 and 410 ( in Figure 
5A) still largely exceeds the 3/11 binding, additional binding of these anchor residues can 
only partially explain the superiority of AP33.  
An extensive analysis of the residues present at AA-positions 408 and 410 in E2 envelope 
glycoproteins of a panel of 72 gt1a and 101 gt1b HCV strains within the NIH GenBank HCV 
database shows that these residues are genotype specific (Figure 5B). K-residues are 
observed much more frequently at position 408 and 410 in gt1a- and gt1b-strains, 
respectively. Based on the presence of K-residues in natural variants and its involvement in 
AP33-binding, we conclude that AP33, but not 3/11, is a relevant candidate for neutralization 
of gt1-infected patient-derived virions. 
 
mAb AP33 protects humanized mice against a patient-derived HCV challenge. 
The in vivo protection capacity of mAbs AP33 and 3/11 was compared using mice with a 
humanized liver (46, 47). Chimeric mice were injected with 1 mg of either antibody and three 
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days later, they were challenged with a 100% infectious dose of mouse passaged P05 virus 
(mLT_P05). Clonal sequence analysis based on the diversity observed at AA384-427 showed 
that the inoculum was composed of 66% P05_VF, 28% P05_VE and 6% P05_VL variants. 
Interestingly, in the LT_P05_VL variant, an asparagine to threonine mutation was observed at 
position 415 (N415T), one of the critical residues of both the AP33 and 3/11 epitope. In contrast 
to AP33-treated mice, of which only one became infected (K1149RR), HCV-RNA could be 
readily detected in 3 out of 4 mice loaded with mAb 3/11 (Figure 6A). Compared to the control 
mice, there was no delay in the kinetics of the infection in the treated, but non-protected mice. 
This is in contrast to previous in vivo challenge studies using polyclonal antibodies (15, 17). 
Although the overall human albumin levels were comparable between the different treatment 
groups, it is worth noting that the non-infected 3/11-treated mouse has the lowest huAlb 
concentration (3.2 mg/mL), whereas the infected AP33-treated mouse has the highest huAlb 
concentration (10.0 mg/mL).  
We sequenced the E1E2 region of the virions that were isolated one week after viral challenge 
from the plasma of the control mice and the mAb-treated mice that became infected. The virion 
diversity in control and 3/11-treated mice was comparable to that of the inoculum (Figure 6B), 
with a dominant presence of variant LT_P05_VF. Mutations in the region spanning the AP33 
and 3/11 epitope were identified in a limited number of clones isolated from control (4 out of 62 
clones) as well as 3/11-treated mice (2 out of 46 clones). The HCV-RNA
+
 AP33-treated mouse 
became infected with a monophyletic viral pool that was uniquely composed of variant P05_VF 
with a conserved antibody-binding region. In 1 out of 14 clones generated from control animal 
B311 we identified the E655G mutation that was previously described to be associated with 
decreased sensitivity to AP33 (50). The mutations S501N, V506A and N415Y described 
previously (50, 51) to affect the potency of the two mAbs were not detected in any of the viral 
clones analyzed in this study.  
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Discussion. 
HCV infection of the graft in patients with detectable serum HCV RNA at time of LT occurs 
immediately, is universal and greatly compromises patient and graft survival. While DAA are 
currently evaluated for prevention (4) and treatment (5, 6) of liver graft infection, a clinically 
approved strategy for prevention of liver graft infection is still absent. Our previous functional 
studies have demonstrated that viral entry and escape from antibody-mediated neutralization 
are key factors defining HCV reinfection in LT suggesting that cross-neutralizing antibodies 
targeting conserved epitopes within the HCV envelope region may be a viable antiviral strategy 
to prevent HCV recurrence (43, 45, 52).  
In the present study, we compared the ability of two well-characterized neutralizing anti-E2 
mAbs targeting the same conserved region, AA412-423, to neutralize patient-derived viral 
variants and to protect mice against a patient-derived HCV challenge. The therapeutic potential 
of this region as an antiviral target is strengthened by its conserved nature and its seemingly low 
natural immunogenicity, evidenced by the very low prevalence of Abs directed to this epitope in 
chronically infected patients (53). Using a LT-patient-derived viral inoculum we demonstrate for 
the first time that anti-E2 antibody AP33 can protect humanized mice against HCV genotype 1b 
challenge in vivo. Despite targeting the same region, mAb 3/11 failed to prevent infection of 
humanized mice challenged with the same isolate. 
Several anti-E2 mAbs have been reported (AP33, 3/11, HCV1 and 95-2) that recognize 
epitopes within AA412-423 (29, 37). This region encompasses the highly conserved E2 residue 
W420, which plays an essential role in CD81 binding and represents a critical contact residue 
for the four mAbs (54). Previous studies using prototype HCV strains showed that the four Abs 
broadly neutralize the most common HCV genotypes in vitro, although IC50 differ between 
isolates (29, 39, 40). Here, we show that although both mAbs neutralize infection of the 
prototype and patient-derived viral variants, the neutralizing potential of AP33 is greater 
compared to 3/11. Furthermore, using the HCVcc system we demonstrate that AP33 can 
neutralize VL/JFH1, a LT-patient-derived variant that harbors mutations mediating escape from 
neutralizing antibodies through multiple mechanisms and that is resistant to autologous and 
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heterologous serum-derived antibodies as well as to many broadly neutralizing human mAbs 
(43, 45).  
ELISA binding studies show that mAb AP33 had a 3- to 15-fold higher relative affinity to 
prototype and patient-derived viral variants compared to 3/11. Sequence analysis of the AA-
region 412-423 of H77c (1a) and patient-derived viral variants (1b) didn’t reveal any AA 
differences within this region, suggesting that additional AA residues in the E1E2 envelope 
glycoprotein contribute to optimal binding. Epitope mapping by expanding binding analysis 
upstream of AA412-423, demonstrates that K-residues at AA-positions 408 and 410 largely 
contribute to AP33-binding. The 3/11 binding was not influenced by AA-changes at these 
positions. Since K-residues are abundantly present at AA-positions 408 and 410 in natural gt1 
variants, these additional anchor residues may explain the increased binding affinity and 
neutralization potential of AP33. Furthermore, differences in the length of the heavy chain CDR3 
previously described between AP33 and 3/11 may also explain binding differences between the 
two mAbs (39).  
Recently Meola and colleagues reported that the epitope targeted by AP33 and 3/11 may adopt 
different conformations that are influenced by up- and downstream sequences (41). In addition 
they showed that HVR1 hampers the binding of 3/11 to soluble E2 while it contributed to the 
stability of the AP33-glycoprotein complex. The additional contact residues mentioned above 
could be responsible for this increased binding stability and neutralization capacity of AP33; or 
they may at least modulate the structure of the epitope towards the orientation that is favored by 
AP33. 
Here, in vivo data using a patient-derived viral challenge, demonstrate that AP33 at doses of 
100 mg/Kg can protect 3 out of 4 mice against HCV infection. Treatment with 3/11, however, 
protected only 1 of 4 mice and no delay in the kinetics of infection were observed. Sequence 
analysis of E1E2 envelope glycoproteins of viral variants detected after viral rebound in the 
treated mice showed no relevant mutations in the 412-423 region. Furthermore, minor mutations 
observed outside this region were similar to those detected in viral variants that became 
Page 14 of 37
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
15 
dominant in the control mice, indicating that these were random mutations rather than the 
consequence of viral escape.  
These data clearly demonstrate that despite sharing the same conserved epitope, mAb AP33 
shows an increased neutralizing capacity compared to mAb 3/11, which is in line with its higher 
affinity and neutralizing capacity in both the HCVpp and HCVcc systems. In contrast to most 
recently published studies that use “prototype” strains for neutralization assays and animal 
challenge, the present study was performed using viral variants derived from LT-patients and 
results in comparable in vitro and in vivo neutralization data. Patient-derived variants probably 
better reflect “real life” HCV reinfection of the liver graft and may therefore be a superior tool for 
anti-HCV mAbs evaluation. 
Until now, only few anti-HCV mAbs have been tested in an in vivo setting. The human mAb 
MBL-HCV1 was recently evaluated for its neutralizing capacity in chimpanzees and humans 
(32, 35). In preclinical evaluation, MBL-HCV1 was infused into two chimpanzees at doses of 
50 and 250 mg/Kg, respectively, 30 minutes prior to challenge with 32 CID of H77c genotype 
1a virus. Only the chimpanzee receiving 250 mg/Kg MBL-HCV1 was protected while the 
chimpanzee receiving 50 mg/Kg was not protected (32). In a pilot clinical study, multiple 
infusions of mAb MBL-HCV1 at doses of 50 mg/Kg delayed the median time to viral rebound 
compared to placebo treatment in HCV-patients undergoing LT, but failed to prevent HCV 
reinfection of the liver graft (35). Since the primary goal - prevention of infection - was not 
achieved in this study, more potent mAbs are still welcome. Although AP33 and MBL-HCV1 
target approximately the same region in E2, they appear to have different characteristics: i) 
when complexed with epitope peptides they have a different structural orientation (40, 55-
57); ii) the major determinants within the minimal binding epitope are different (29, 39); iii) we 
here defined additional epitope residues important for AP33 binding; and iv) AP33 is 
endowed with higher neutralizing capacities (57).  
These findings led to our in vivo experiments and form the major rationale for performing the 
present study. Using a similar set-up with humanized uPA-SCID mice Law et al. evaluated 
the ability of 6 human mAbs against an HCV challenge with patient-derived serum (gt 1a). In 
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this set-up, 2 out of 5 mice receiving mAb AR3A and 3 out of 4 mice receiving mAb AR3B 
were still protected. However, high concentrations of mAbs (200 mg/Kg) were required for 
protection precluding their future use in humans (22). In the present study we demonstrate 
the efficacy of mouse AP33 at 100 mg/Kg against pre-transplant viral variants. The recent 
humanization of mAb AP33 (55) warrants further exploration in a human setting, not only 
during LT but also as a safe and efficient immunoprophylactic approach before LT to 
decrease viral load in circulation.  
 
  
Page 16 of 37
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
17 
Acknowledgements  
The authors are grateful to Dr. F.-L. Cosset (Inserm U1111, ENS Lyon, France) for retroviral 
vectors and expression plasmids for HCVpp production, Dr. F. V. Chisari (The Scripps 
Research Institute, La Jolla, USA), Dr. C. M. Rice (The Rockefeller University, NY, USA) for the 
gift of Huh7.5.1 cells, and Drs. C. M. Rice (the Rockefeller University), Dr. T. Wakita (University 
of Tokyo, Japan) and Dr. R. Bartenschlager (University of Heidelberg, Germany) for providing 
chimeric JFH1-based and Jc1 HCVcc expression plasmids.  
Page 17 of 37
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
18 
Figure legends 
Figure 1. Binding characteristics of mAbs AP33 and 3/11. Cell-lysates containing HCV E1E2 
envelope glycoproteins derived from prototype isolates (H77c, JFH1, J4) and patient-derived 
viral isolates (gt1b) selected during liver graft infection (LT_P05_VD, LT_P05_VE, LT_P05_VF) 
or selected during transmission to humanized mice (CC_P08_VD, CC_P09_VA, CC_P12_VA) 
were incubated with serially diluted mAbs AP33 and 3/11 for 1 hour at room temperature. Bound 
antibodies were detected with an HRP-conjugated anti-species secondary antibody. 
Absorbance values were determined at 450 nm. Dose response binding, expressed as 
percentage of maximal binding in EIA (means +/- SEM), (A) and EC50 (B) are shown. The 
difference in EC50-values between mAbs AP33 and 3/11 can be considered very significant 
(P=0,0039). 
 
Figure 2. Neutralizing properties of mAbs AP33 and 3/11. HCVpp expressing envelope 
glycoproteins derived from viral isolates selected during liver graft infection (LT_P05_VD, 
LT_P05_VE and LT_P05_VF)(A) or selected during transmission to humanized mice 
(CC_P09_VA, CC_P09_VB, CC_P10_VA and CC_P12_VA) (B) were incubated for 1 hour at 
37°C with serial dilutions (µg/mL) of mAbs 3/11 or AP33 and added to primary human 
hepatocytes (panel A) or Huh7.5.1 cells (panel B). HCVpp entry was analyzed by luciferase 
reporter gene expression and normalized to isotype control. Means +/- SD from one 
representative experiment (performed in triplicate) out of two independent experiments are 
shown. The results of the experiments in panel A and B were pooled for statistical analysis and 
the difference in IC50-values between mAbs AP33 and 3/11 were significant (P=0.0039). (C) 
HCVcc Jc1 and chimeric HCVcc expressing the structural proteins from a liver transplant 
escape variant (LT_P01_VL/JFH1) were incubated for 1 hour at 37°C with 10 µg/mL of mAbs 
3/11 or AP33 and added to Huh7.5.1 cells. HCVcc infectivity was determined by the TCID50 
assay and normalized to experiments using isotype control antibody. The results are expressed 
as percentage of HCVcc infectivity and error bars represent the standard error of the mean. The 
asterisks (*P<0.05, **P<0.01) indicate statistically significant differences, whereas ‘ns’ stands for 
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not significantly different. (D) Alignment of the amino acid sequence of the envelope region 
spanning AA384-427 of the different CC and LT patient isolates.  
 
Figure 3. AP33, but not 3/11, inhibits viral cell entry of HCVpp expressing patient-derived 
envelopes from variants isolated before and after LT. HCVpp expressing envelope 
glycoproteins derived from HCV-prototype strains (H77c (gt1a) and HCV-J (gt1b)) and from viral 
isolates derived from LT-patients were pre-incubated for 1 hour at 37°C with mAbs AP33, 3/11 
or isotype monoclonal control IgG (10 µg/mL) and added to primary human hepatocytes. 
HCVpp entry was analyzed by luciferase reporter gene expression and normalized to isotype 
control IgG. Escape variants selected after LT are marked with an asterisk. All conditions were 
performed in triplicate and the results are expressed as mean of percentage of HCVpp entry. 
Error bars show the standard deviation (SD).  
 
Figure 4. Binding pattern for mAb AP33 and 3/11 is different for gt1a- and gt1b-derived 
sequences. The binding pattern of mAb 3/11 and AP33 was compared using gt1a- (H77c) and 
gt1b- (LT_P05_VF and CC_P08_VA) derived peptide sequences. MAbs were incubated with 
surface-attached peptides (25 µg/mL) and bound antibodies were detected with an HRP-
conjugated anti-species secondary antibody. Absorbance values were determined at 450 nm. 
(A) Binding pattern of 3/11 and AP33 (10 µg/mL) using overlapping peptides (15-mer with 1 AA 
overlap) spanning AA-region 406-427 of E2. The binding affinity was normalized to peptide 
AA384-447-binding (100% binding). The AA-sequence alignment of E2-region AA384-447 and 
the overlapping peptides covering AA-region 406-427 from the different strains are shown. AA 
at positions 408 and 410 are marked in bold. (B) Serial dilutions of mAbs 3/11 or AP33 were 
incubated with (i) functional E1E2-cell lysates (E1E2_FL, marked red), (ii) peptides spanning 
AA384-447 and (iii) peptides with superior binding in Figure 4A.  
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Figure 5. Lysine-residues upstream of the conserved epitope 412-423 are important for 
mAb AP33 binding. (A) The binding pattern of mAb 3/11 and AP33 was compared using wild 
type or mutated patient-derived peptides spanning AA-region 406-427. Serial dilutions of mAbs 
were incubated with surface-attached peptides (25 µg/mL) and bound antibodies were detected 
with an HRP-conjugated anti-species secondary antibody. Peptides were generated with K- or 
A-substitutions at positions 408 and/or 410 (H77c: K408A, N410K, N410A, and double mutants 
K408A-N410K and K408A-N410A; LT-P05_VF: T408A, T408K, K410A, and double mutants 
T408K-K410A and T408A-K410A; CC-P08_VA: A408K, K410A, and double mutant A408K-
K410A). The resulting peptide sequences are shown and changed AA marked. Dots indicate 
AA-similarity. (B) Distribution of AA-residues at positions 408 and 410 of HCV E2 sequences in 
a panel of 72 gt1a and 101 gt1b HCV-strains within the Genebank (NIH) HCV database.  
 
Figure 6. mAb AP33 protects humanized mice against an HCV-gt 1b challenge. (A) 
Chimeric animals were challenged with 104 IU HCV RNA of mLT_P05 without pretreatment (no 
IgG) or after passive immunization on day -3 with 1 mg of mAb 3/11 or AP33. Plasma HCV RNA 
levels (IU/mL) were measured until 8 weeks after viral challenge. Mice that remained non-
infected after inoculation are shown as HCV-RNA <750 IU/ml (LOQ, dotted line). Animal 
B338RL died 4 weeks after viral challenge. (B) Clonal sequence analysis of recovered virions in 
selected week 1 samples (week 2 for B311R) revealed viable E1E2 sequences in all samples. 
Each color represents a unique sequence in AA-region 384-427 (left panel). Columns represent 
the percentage of each clone detected in the inoculum or in the plasma of the animals. For each 
animal, the total number of clones analyzed is shown beneath the mouse ID. Viral outcome after 
mLT_P05 challenge is summarized as % protection. The sequence of each quasispecies clone 
is shown in the right panel. AA highlighted in red, represent AP33 anchor residues identified in 
this and previous papers.  
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Figure 1. Binding characteristics of mAbs AP33 and 3/11. Cell-lysates containing HCV E1E2 envelope 
glycoproteins derived from prototype isolates (H77c, JFH1, J4) and patient-derived viral isolates (gt1b) 
selected during liver graft infection (LT_P05_VD, LT_P05_VE, LT_P05_VF) or selected during transmission to 
humanized mice (CC_P08_VD, CC_P09_VA, CC_P12_VA) were incubated with serially diluted mAbs AP33 
and 3/11 for 1 hour at room temperature. Bound antibodies were detected with an HRP-conjugated anti-
species secondary antibody. Absorbance values were determined at 450 nm. Dose response binding, 
expressed as percentage of maximal binding in EIA (means +/- SEM), (A) and EC50 (B) are shown. The 
difference in EC50-values between mAbs AP33 and 3/11 can be considered very significant (P=0,0039).  
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Figure 2. Neutralizing properties of mAbs AP33 and 3/11. HCVpp expressing envelope glycoproteins 
derived from viral isolates selected during liver graft infection (LT_P05_VD, LT_P05_VE and LT_P05_VF)(A) 
or selected during transmission to humanized mice (CC_P09_VA, CC_P09_VB, CC_P10_VA and CC_P12_VA) 
(B) were incubated for 1 hour at 37°C with serial dilutions (µg/mL) of mAbs 3/11 or AP33 and added to 
primary human hepatocytes (panel A) or Huh7.5.1 cells (panel B). HCVpp entry was analyzed by luciferase 
reporter gene expression and normalized to isotype control. Means +/- SD from one representative 
experiment (performed in triplicate) out of two independent experiments are shown. The results of the 
experiments in panel A and B were pooled for statistical analysis and the difference in IC50-values between 
mAbs AP33 and 3/11 were significant (P=0.0039). (C) HCVcc Jc1 and chimeric HCVcc expressing the 
structural proteins from a liver transplant escape variant (LT_P01_VL/JFH1) were incubated for 1 hour at 
37°C with 10 µg/mL of mAbs 3/11 or AP33 and added to Huh7.5.1 cells. HCVcc infectivity was determined 
by the TCID50 assay and normalized to experiments using isotype control antibody. The results are 
expressed as percentage of HCVcc infectivity and error bars represent the standard error of the mean. The 
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asterisks (*P<0.05, **P<0.01) indicate statistically significant differences, whereas ‘ns’ stands for not 
significantly different. (D) Alignment of the amino acid sequence of the envelope region spanning AA384-
427 of the different CC and LT patient isolates.  
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Figure 3. AP33, but not 3/11, inhibits viral cell entry of HCVpp expressing patient-derived 
envelopes from variants isolated before and after LT. HCVpp expressing envelope glycoproteins 
derived from HCV-prototype strains (H77c (gt1a) and HCV-J (gt1b)) and from viral isolates derived from LT-
patients were pre-incubated for 1 hour at 37°C with mAbs AP33, 3/11 or isotype monoclonal control IgG (10 
µg/mL) and added to primary human hepatocytes. HCVpp entry was analyzed by luciferase reporter gene 
expression and normalized to isotype control IgG. Escape variants selected after LT are marked with an 
asterisk. All conditions were performed in triplicate and the results are expressed as mean of percentage of 
HCVpp entry. Error bars show the standard deviation (SD).  
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Figure 4. Binding pattern for mAb AP33 and 3/11 is different for gt1a- and gt1b-derived 
sequences. The binding pattern of mAb 3/11 and AP33 was compared using gt1a- (H77c) and gt1b- 
(LT_P05_VF and CC_P08_VA) derived peptide sequences. MAbs were incubated with surface-attached 
peptides (25 µg/mL) and bound antibodies were detected with an HRP-conjugated anti-species secondary 
antibody. Absorbance values were determined at 450 nm. (A) Binding pattern of 3/11 and AP33 (10 µg/mL) 
using overlapping peptides (15-mer with 1 AA overlap) spanning AA-region 406-427 of E2. The binding 
affinity was normalized to peptide AA384-447-binding (100% binding). The AA-sequence alignment of E2-
region AA384-447 and the overlapping peptides covering AA-region 406-427 from the different strains are 
shown. AA at positions 408 and 410 are marked in bold. (B) Serial dilutions of mAbs 3/11 or AP33 were 
incubated with (i) functional E1E2-cell lysates (E1E2_FL, marked red), (ii) peptides spanning AA384-447 and 
(iii) peptides with superior binding in Figure 4A.  
190x254mm (300 x 300 DPI)  
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Figure 5. Lysine-residues upstream of the conserved epitope 412-423 are important for mAb 
AP33 binding. (A) The binding pattern of mAb 3/11 and AP33 was compared using wild type or mutated 
patient-derived peptides spanning AA-region 406-427. Serial dilutions of mAbs were incubated with surface-
attached peptides (25 µg/mL) and bound antibodies were detected with an HRP-conjugated anti-species 
secondary antibody. Peptides were generated with K- or A-substitutions at positions 408 and/or 410 (H77c: 
K408A, N410K, N410A, and double mutants K408A-N410K and K408A-N410A; LT-P05_VF: T408A, T408K, 
K410A, and double mutants T408K-K410A and T408A-K410A; CC-P08_VA: A408K, K410A, and double 
mutant A408K-K410A). The resulting peptide sequences are shown and changed AA marked. Dots indicate 
AA-similarity. (B) Distribution of AA-residues at positions 408 and 410 of HCV E2 sequences in a panel of 72 
gt1a and 101 gt1b HCV-strains within the Genebank (NIH) HCV database.  
190x254mm (300 x 300 DPI)  
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Figure 6. mAb AP33 protects humanized mice against an HCV-gt 1b challenge. (A) Chimeric animals 
were challenged with 104 IU HCV RNA of mLT_P05 without pretreatment (no IgG) or after passive 
immunization on day -3 with 1 mg of mAb 3/11 or AP33. Plasma HCV RNA levels (IU/mL) were measured 
until 8 weeks after viral challenge. Mice that remained non-infected after inoculation are shown as HCV-RNA 
<750 IU/ml (LOQ, dotted line). Animal B338RL died 4 weeks after viral challenge. (B) Clonal sequence 
analysis of recovered virions in selected week 1 samples (week 2 for B311R) revealed viable E1E2 
sequences in all samples. Each color represents a unique sequence in AA-region 384-427 (left panel). 
Columns represent the percentage of each clone detected in the inoculum or in the plasma of the animals. 
For each animal, the total number of clones analyzed is shown beneath the mouse ID. Viral outcome after 
mLT_P05 challenge is summarized as % protection. The sequence of each quasispecies clone is shown in the 
right panel. AA highlighted in red, represent AP33 anchor residues identified in this and previous papers.  
190x254mm (300 x 300 DPI)  
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Supplementary Figure 1: Bioavailability of circulating mAb AP33 and 3/11 in immunized 
mice. After viral challenge, the presence of mAb 3/11 in 3/11-treated (A) and of AP33 in AP33-
treated (B) uPA-SCID mice was measured using EIA. Cell-lysates containing HCV E1E2 
envelope proteins derived from prototype isolate H77c were incubated with 3 dilutions of mouse 
plasma (1/5, 1/10 and 1/20) for 1 hour at room temperature. Bound antibodies were detected 
with an HRP-conjugated anti-species secondary antibody. Absorbance values were determined 
at 450 nm. For a semi-quantitative estimation of the circulating mAb-level, dilutions of both 
mAbs were added in parallel (termed ‘standard’). In each set-up, the plasma of two control mice 
was added. The suffix added to the mouse ID number refers to the day of plasma collection. 
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Supplementary Table 1 for online publication 
 
 
Supplementary Table 1.  Neutralizing properties of mAbs AP33 and 3/11* 
 
*IC50-results (μg/mL) of the HCVpp-experiments shown in Figure 2 panel A and B. 
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 1 
Detailed Materials and Methods for online publication. 
 
Primary human hepatocytes, cell lines and monoclonal antibodies. Primary human 
hepatocytes (PHH) were obtained from patients undergoing partial liver resection. 
Huh7.5.1, HEK293FT and HEK293T cell lines have been described previously (1, 2). 
The isolation and production of the anti-HCV E2 mouse mAb AP33 and the rat anti-E2 
mAb 3/11 have been described previously (3-6). 
 
Patient-derived HCV-variants. A first group of viral variants used in the in vitro 
experiments (Figure 1 and 2) and termed LT_P0#_variant, originates from post-LT 
serum isolated from HCV-infected patients that underwent LT and became re-infected. 
These variants, selected during liver graft infection, are considered as LT escape 
variants. Human pre-transplant serum from LT_P05 was injected in uPA+/+-SCID mice, 
resulting in mouse plasma with a restricted diversity mimicking the post-LT human serum 
(7). This mouse-passaged P05 virus (termed mLT_P05 in Figure 6) lacks the patient’s 
neutralizing antibodies and was used as the challenge virus in the in vivo experiments. A 
second group of viral variants used in the in vitro experiments and termed 
CC_P0#_variant, originates from purified B-lymphocytes isolated from HCV-gt1b 
infected chronic carriers that were injected in chimeric uPA+/+-SCID mice. After passage, 
the infectious mouse plasma was mostly composed of a single viral variant (used to 
generate HCVpp), reflecting variant-selection during transmission to humanized mice 
and escape from the patients’ humoral immune response (Desombere et al., HCV-
genotype 1b escapes antibody-mediated neutralization by viral transmission through 
peripheral blood B-lymphocytes, meeting abstract P5.06 at the 21st International 
Symposium on Hepatitis C Virus and Related Viruses, September 7-11, 2014, Banff, 
Canada). 
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 2 
GNA-capture and peptide binding ELISA. To measure the relative binding affinity of 
mAbs AP33 and 3/11 to HCV E1E2 glycoproteins, a cell-lysate based ELISA was 
performed as previously described (8). Briefly, HEK-293T cells were transfected with 
plasmids expressing the E1E2 glycoproteins of (i) prototype isolates H77c (gt1a), JFH1 
(gt2a) and J (gt1b) (9), (ii) LT-escape variants P05_VD, P05_VE and P05_VF (gt1b), 
and (iii) chronic carrier (CC)-variants P08_VD, P09_VA and P12_VA (gt1b). Optimal 
dilution of E1E2 lysates derived from transfected HEK-293T cells was determined using 
GNA (Galanthus nivalis) lectin-coated microtiter plates (Sigma). To measure the relative 
affinity of mAbs AP33 and 3/11 to different peptides, a standard ELISA was performed 
wherein peptides (25 µg/mL) were surface-attached using a 50mM carbonate-
bicarbonate buffer (pH9.6). Synthetic peptides were obtained from JPT Peptide 
Technologies GmbH (Berlin, Germany) (>95% purity) and dissolved in water plus 10% 
dimethyl sulfoxide (DMSO) at 10 mg/ml. AP33 and 3/11 were serially diluted and 
incubated for 1 hour at room temperature. Bound antibodies were detected with an 
HRP-conjugated anti-species secondary antibody. Absorbance values were determined 
at 405 nm. Results were expressed as % of maximal binding. 
 
HCVpp and HCVcc production, infection and neutralization. Lentiviral HCVpp 
expressing patient-derived envelope glycoproteins were produced as previously 
described (7, 10-11). HCVpp entry was determined by measuring the luciferase reporter 
gene expression. The detection limit for positive luciferase reporter protein expression 
was 3x103 RLU/assay corresponding to the mean ± 3 SD of background levels, i.e. 
luciferase activity of naïve non-infected cells or cells infected with pseudotypes without 
HCV envelopes. Patient-derived HCVpp infectivity in PHH and Huh7.5.1 ranged from 
7x103 to 9x105 RLU and 3x105 to 2x106 RLU, respectively. Chimeric HCVcc expressing 
patient-derived structural proteins have been produced previously and their infectivity 
was determined by the TCID50 assay in Huh7.5.1 cells (12). HCVpp and HCVcc 
neutralization were performed as described (2, 7, 13). Briefly, HCVpp or HCVcc were 
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mixed with mAbs AP33, 3/11 or control isotype IgG, pre-incubated for 1 hour at 37°C 
and added to PHH (for HCVpp) or Huh7.5.1 cells (for HCVpp and HCVcc) for 72 hours 
at 37°C. For dose-dependent response, mAbs were serially diluted to determine the 
IC50, the concentration of antibody that gave a 50% inhibition of HCVpp entry. The 
specific neutralization was determined as described (7). Background levels of HCVpp 
and HCVcc infection were taken into account by subtracting infectivity in the presence 
of irrelevant isotype control IgG used at the same dilution as for anti-HCV mAbs. 
 
Sequencing analysis. Clonal sequence analysis was performed on all HCV-positive 
mouse samples and the inoculum. Briefly, total RNA was purified from plasma using the 
High Pure Viral Nucleic Acid kit (Roche) and converted into cDNA using Superscript™III 
Reverse Transcriptase (Invitrogen) and random primers (125 ng/µL). The region 
spanning the C-terminal part of core and the full-length E1E2 region was amplified using 
LongAmp DNA polymerase (NEB) using the following primers: 5'-CGTAGGTC-
GCGTAACTTGGGTAA-3' and 5'-GTGCGCCTCGGCTCTGGT-GATAAA-3'. A second, nested PCR 
was performed using Pfu DNA polymerase (Fermentas) and the following primers: 5'-
TATAGATATCATGGGGTACATCCGCTCGTC-3' and 5'-ATATGATATCTTACTCAGCCTGAGCTATCAG-3' 
(2). The generated amplicons were then run on a 1% agarose gel, purified and cloned 
into the Zero Blunt cloning vector (Invitrogen). After transformation, 9 to 20 clones were 
sequenced on an ABI3730XL DNA analyzer (Applied Biosystems), using plasmid (M13) 
and HCV-specific (5’-TGGGATATGATGATGAACTGGTC-3’, 5’-AGGGCAGTCCTGTTGATGTGCCAG-
CTGCC-3’, 5’-TGCCCCACGGACTGCTTCCGGA-3’, 5’-CCTTCAGACCGGGTTCCTTG-3’ and 5’-CATG-
CRGCATTGAGCCTGTG-3’) primers. 
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